Stay updated on Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study details related to a Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab for patients with advanced or metastatic Renal Cell Carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:01.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying inclusion and exclusion criteria for participants with advanced or metastatic renal cell carcinoma. Previously, no information was provided in this section.
    Difference
    17%
    Check dated 2024-05-22T19:38:58.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage. This change likely indicates a shift in the type of intervention or navigation options related to medical and healthcare publications and documentation.
    Difference
    0.6%
    Check dated 2024-05-01T15:54:25.000Z thumbnail image

Stay in the know with updates to Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial page.